VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2.
Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A.
Ziogas AC, et al. Among authors: rodolakis a.
Int J Cancer. 2012 Feb 15;130(4):857-64. doi: 10.1002/ijc.26094. Epub 2011 May 25.
Int J Cancer. 2012.
PMID: 21445972
Free article.